VRNA Verona Pharma plc

Nasdaq veronapharma.com


$ 106.98 $ 0.12 (0.11 %)    

Monday, 06-Oct-2025 16:18:04 EDT
QQQ $ 612.11 $ 7.61 (1.26 %)
DIA $ 467.12 $ 5.24 (1.13 %)
SPY $ 671.75 $ 6.91 (1.04 %)
TLT $ 91.68 $ 0.35 (0.38 %)
GLD $ 401.36 $ 14.16 (3.64 %)
$ 106.91
$ 106.85
$ 0.00 x 0
$ 0.00 x 0
-- - --
$ 31.09 - $ 106.93
1,871,959
na
10.37B
$ 1.47
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2025 06-30-2025 10-Q
2 04-29-2025 03-31-2025 10-Q
3 02-27-2025 01-01-1970 10-K
4 11-04-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-10-2024 03-31-2024 10-Q
7 02-29-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 03-07-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-03-2022 03-31-2022 10-Q
15 03-03-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 04-29-2021 03-31-2021 10-Q
19 02-25-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cantor-fitzgerald-suspends-overweight-rating-on-verona-pharma-plc-adr-maintains-100-price-target

Cantor Fitzgerald suspends Overweight rating on Verona Pharma PLC ADR (NASDAQ:VRNA) and Maintains $100 price target

 verona-pharma-announces-that-high-court-of-justice-of-england-and-wales-has-approved-its-acquisition-by-msd-for-107-per-american-depository-share-totaling-10b

Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma"), a biopharmaceutical company focused on respiratory diseases, which e...

Core News & Articles

LONDON, U.K., and RALEIGH, N.C., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma"), ...

 verona-pharma-q2-eps-013-beats-004-estimate-sales-103138m-beat-92140m-estimate

Verona Pharma (NASDAQ:VRNA) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $0.04 b...

 hc-wainwright--co-downgrades-verona-pharma-to-neutral-raises-price-target-to-107

HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Verona Pharma (NASDAQ:VRNA) from Buy to Neutral and raises the...

 wells-fargo-downgrades-verona-pharma-to-equal-weight-lowers-price-target-to-107

Wells Fargo analyst Tiago Fauth downgrades Verona Pharma (NASDAQ:VRNA) from Overweight to Equal-Weight and lowers the price ...

 btig-downgrades-verona-pharma-to-neutral

BTIG analyst Thomas Shrader downgrades Verona Pharma (NASDAQ:VRNA) from Buy to Neutral.

 jefferies-downgrades-verona-pharma-to-hold-lowers-price-target-to-107

Jefferies analyst Suji Jeong downgrades Verona Pharma (NASDAQ:VRNA) from Buy to Hold and lowers the price target from $140 t...

 canaccord-genuity-downgrades-verona-pharma-to-hold-announces-107-price-target

Canaccord Genuity analyst Edward Nash downgrades Verona Pharma (NASDAQ:VRNA) from Buy to Hold and announces $107 price target.

 nvidias-4-trillion-milestone-lifts-wall-street-whats-moving-markets-wednesday

Wall Street rose on Wednesday as investors shrugged off fresh trade uncertainty after the White House delayed the start of new ...

 merck-strikes-10-billion-deal-for-verona-secures-first-in-class-copd-drug

Merck is acquiring Verona Pharma for $10 billion, gaining COPD drug Ohtuvayre as part of its strategy to offset Keytruda's ...

Core News & Articles

Acquisition aligns with Merck's science-led business development strategy and expands pipeline and portfolio of treatments ...

Core News & Articles

https://www.ft.com/content/bf1c2253-15b3-426a-975d-15ddca1d84a5https://www.ft.com/content/bf1c2253-15

 why-aes-shares-are-trading-higher-by-over-10-here-are-20-stocks-moving-premarket

Shares of The AES Corporation (NYSE:AES) rose sharply in pre-market trading following reports the company has received takeover...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION